

QIBA Diffusion-Weighted Imaging MR Biomarker Committee (BC) Meeting

Wednesday, June 15, 2022, at 1 pm (CT)

Meeting Summary

Participants

Dariya Malyarenko, PhD (Co-chair)

Trevor Andrews, PhD

Ishtiaq Bercha, MSc, MSEE

Thomas Chenevert, PhD

Matt Hall, PhD

Wen Li, PhD

Jiacho Liang, PhD

Daniel Margolis, MD

Kevin Miller, MS

Peter Ngum, MSc

Nancy Obuchowski, PhD

Savannah Partridge, PhD

Lisa Wilmes, PhD

Jie Zheng, PhD

RSNA

Susan Stanfa

Topics:

- Rebuttal for VERDICT ADC repeatability paper
- White paper plans
- Progress update re: Technical Confirmation site feedback and incorporation into the Profile

Next Steps / Action Items:

- Follow-up meeting needed to work on the rebuttal for the VERDICT ADC repeatability paper
 - VERDICT received comments from *Radiology: Imaging Cancer*, 90% of which were statistical in nature
 - Dr. Obuchowski has drafted responses and additional work is needed on calculations
 - Drs. Malyarenko and Obuchowski to meet on June 16 and submit their feedback to VERDICT
- The Google Doc outline of the white paper and writing assignments were reviewed
 - Dr. Boss, will work on Claims section with Drs. Dave and Obuchowski
 - Dr. Obuchowski to address statistics and performance metrics
 - Drs. Attariwala, Bercha, and Partridge to work on an introduction that will focus on the importance and value of quantitation in DWI-MR
 - Dr. Malyarenko to address DRO usage while Drs. Chenevert and Mr. Miller to draft text re: conformance testing with a physical phantom
 - Dr. Bercha to work on “gaps” and Dr. Hall on quality assurance
 - QIBA terminology, e.g., “actors”, was identified as a barrier to reader accessibility and Drs. Andrews and Hall volunteered to translate the QIBA-centric terminology into a more user-friendly language
 - The goal of the white paper is to explain how to implement the reproducible and repeatable elements of ADC as part of a clinical trial; a baseline is achievable by following the Profile
 - Suggestion to state explicitly that the Profile provides a baseline that should be met before adapting it to more advanced quantitative methods
 - To appeal to a wider audience of potential users, use of Profiles in clinical trials as well as in routine clinical practice to be discussed
 - White paper authors can reference the DWI Consensus Profile on the [QIBA Wiki](#)
 - Staff to forward the email addresses of Drs. Andrews, Bercha, Hall, Margolis, Ngum, and Obuchowski to Dr. Boss and request access to the Google Doc on their behalf
 - Fall is the target for completing a draft
- The DWI Technical Confirmation Task Force has reached consensus on all comments and about 80% of changes have been incorporated into the Profile
 - After remaining changes have been incorporated into the Profile, BC Internal Review of implemented resolutions will be requested, followed by initiation of BC then MR CC votes-to-publish as Technically Confirmed

Next DWI-MR BC Meeting: Wednesday, July 20, 2022, at 1 p.m. (CT)

Zoom meeting link: <https://rsna-org.zoom.us/j/83547454118?pwd=VU5La0RRYXV5eDRlYzVrQjNGWGZCZz09>

Meeting ID: 835 4745 4118

Passcode: DWI

RSNA Staff attempt to capture all committee members participating in Zoom meetings. However, **if attendees join only by phone, or do not use a recognizable name, identification is not possible.** Participants are welcome to contact RSNA staff at giba@rsna.org if their attendance is not reflected in meeting summaries.